FiftyBidsGovernment contracts and grants, in one plain-English search.

Back to search

Open grant

NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)

This notice of funding opportunity (NOFO) invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified.

FromNational Institutes of Health
Who can applystate governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notesRefer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.)
How muchabout 2 awards
DeadlineFri, May 25, 2029 (945 days left)
CategoryHealth
TypeGrant
Opportunity #PAR-27-083
Assistance listing93.855
PostedThu, May 7, 2026

Open the official posting

From the notice

This notice of funding opportunity (NOFO) invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. This mechanism may also be used to support development of a new resource to the broader scientific community of the National Institute of Allergy and Infectious Diseases (NIAID). It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate.The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.